Search

everythinglearnresearchcommunity

for

Search:↓

Some people who got COVID-19 experienced temporary hair loss starting around 10 weeks after infection, with many seeing improvement within about 25 days.

The document says that hookworms are treated with mebendazole and stress-related hair loss usually gets better in 6 months, while other hair loss types have specific treatments.

COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.

COVID-19 may be linked to hair loss called Telogen Effluvium, affecting quality of life and self-esteem.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.

COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.

Boreal caribou in northeastern British Columbia have significant health issues, including infections, tick infestations, and mineral deficiencies.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

The review found that COVID-19 can cause skin problems, including rashes and issues from wearing PPE, and suggests more research and protective measures for healthcare workers.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

Malarone® caused pancreatitis and hair loss in a dog for the first time.

The boy's hair loss was due to a hair-pulling disorder, not just a fungal infection.

Educators who survived COVID-19 faced physical, psychological, and social challenges but overcame them with resilience and support, highlighting the need for schools to provide better health and psychological care.

COVID-19 vaccines may cause hair loss in people who are genetically prone to it.

A woman lost over 80% of her hair due to a condition called telogen effluvium after having COVID-19.

Hydroxychloroquine may help COVID-19 patients with lupus.

Patients with lupus nephritis and COVID-19 can improve with proper treatment.

Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.

The document lists various dermatology topics, treatments, and diagnostic methods.

Hair changes are common in AIDS patients and can add to their financial and emotional stress.

Alopecia areata's causes are unclear, treatments exist but relapses are common.

Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Thiazole, a sulfur and nitrogen chemical, is useful in creating potential drugs for conditions like seizures, cancer, bacterial infections, tuberculosis, inflammation, malaria, viruses, Alzheimer's, diabetes, and A1-receptor issues.